Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Sangamo Therapeutics Q1 2024 GAAP EPS $(0.27) Misses $(0.22) Estimate, Sales $481.000K Miss $6.654M Estimate

Author: Benzinga Newsdesk | May 09, 2024 04:30pm
Sangamo Therapeutics (NASDAQ:SGMO) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 325 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $481.000 thousand which missed the analyst consensus estimate of $6.654 million by 92.77 percent. This is a 99.70 percent decrease over sales of $157.957 million the same period last year.

Posted In: SGMO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist